rSM PROGRESS. DESTINATION PATIENTS.
Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients.

Press Releases

April 18, 2019
Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA
October 02, 2018
FierceBiotech names Arrakis Therapeutics as one of its “Fierce 15” Biotech Companies of 2018
January 10, 2018
Arrakis Therapeutics Named as an “Endpoints 11” Disruptive Biotech Company of 2017
December 13, 2017
Arrakis Therapeutics Announces Exclusive License to RNA-targeted Small Molecule Technology from the University of Pennsylvania
October 25, 2017
Arrakis Therapeutics Announces Release of SHAPEware™ Bioinformatics Tools as Open-Source Software
May 02, 2017
Arrakis Congratulates Its SAB Chair, Melissa Moore, PhD, on Election to National Academy of Sciences
February 27, 2017
Arrakis Therapeutics Announces $38 Million Series A Financing To Target RNA with Small-Molecule Medicines And Names Michael Gilman Chairman and CEO
HOME | SITEMAP | CONTACT
© 2019 Arrakis Therapeutics. All rights reserved.
Back to Top